Ashion® leverages advanced clinical genomic sequencing and analysis technology developed through research at The Translational Genomics Research Institute® (TGen®). Ashion’s number one priority is to deploy this technology commercially to help more patients. This technology was used in the world’s first clinical studies for personalized cancer treatment selection, and Ashion hopes to continue to partner with research collaborators for impactful clinical studies.
Ashion Analytics™ is proud to partner with TGen as its clinical sequencing provider for several important clinical studies, such as precision medicine trials for brain cancer and multiple myeloma patients, and a multicenter study to evaluate the feasibility of molecularly guided therapy in patients with relapsed or refractory childhood cancers. In these trials Ashion collaborates with dozens of academic and commercial partners across the world to deliver high quality and reliable clinical genomic results.
Ashion Analytics™ has the tools and services to make your clinical research project successful
• Fully interpreted reports for cancer testing, including drug consequences and clinical trial options based on a patient’s somatic mutations. • Analytic whole transcriptome and whole-exome sequencing for clinical researchers who simply need CLIA-validated raw or variant-called data without an interpreted report. • CLIA chain of custody to preserve clinical research samples for follow-on clinical testing • Advanced reporting capabilities, including “white label” services to customize reports for your institution • Tumor/normal sequencing for true distinction of somatic mutation from germline variants. • Advanced, automated QC analyses to identify swapped or cross-contaminated samples. • Data delivery and distribution capabilities to handle multi-center studies • Protocol development, cohort analyses and tumor board services through TGen.